CGC · Canopy Growth Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -3.24M | Three months ended June 30 | — |
| Adjusted EBITDA loss non-GAAP | $3.2M | the first quarter of fiscal 2027 filing | — |
| Adjusted gross margin non-GAAP | 31% | Q1 FY2027 | — |
|
|
|||
| Cannabis segment gross margin percentage | 22% | the three months ended June 30, 2026 filing | — |
| Free cash flow non-GAAP | -25.75M | Three months ended June 30 | — |
GAAP → non-GAAP reconciliationGAAP Net cash used in operating activities -25.01M
-737K Purchases of and deposits on property, plant and equipment
= Free cash flow -25.75M
|
|||
| Gross margin percentage | 27% | the three months ended June 30, 2026 filing | — |
| Storz & Bickel segment gross margin percentage | 48% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGC
this stock
Canopy Growth Corp
|
$382.98M | -22.6% | — | — | 6.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.0% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.7% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGC | -5.0% | -8.8% | -16.0% | -1.5% | -22.6% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -4.6% | -8.7% | -28.4% | -1.7% | -34.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.